Recent News

• 05.14.2025 - Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
• 05.14.2025 - Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
• 04.25.2025 - Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
• 04.25.2025 - Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
• 04.07.2025 - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
• 04.07.2025 - Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Recent Filings

• 05.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.01.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.21.2025 - 3 Initial statement of beneficial ownership of securities
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2025 - 8-K Current report
• 04.07.2025 - EX-99.1 EX-99.1